Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

Elizabeth J. Kelly; Melanie Greenland; Philip de Whalley; Grace C. Macaulay; Parvinder K. Aley; Emma Plested; S Koleva; James Cotton; James Kinch; T Madupuri; Robert C. Read; Mary Ramsay; Claire Cameron; Turner Dpj; Paul T. Heath; Philip Connor; Katrina Cathie; SN Faust; Banerjee; Chiman Kwan; Fiona Shackley; Stephen M. Riordan; Stephen Owens; Theofilos Polychronakis; Hanane Trari Belhadef; Yama F Mujadidi; Anirban Singha; Liberty Cantrell; Elizabeth Clutterbuck; Ralph O. Anslow; Tim James; Bassam Hallis; M Matheson; Lei Chang; Teresa Lambe; Jonathan S. Nguyen‐Van‐Tam; Matthew D. Snape; Angela M. Minassian; Yang Liu

doi:10.1016/j.jinf.2025.106663

December 1, 2025Journal of InfectionOpen Access

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

Immune response improved significantly with heterologous vaccination strategies, resulting in enhanced immunogenicity.
The 10 μg fractional BNT162b2 vaccine showed similar immunogenicity to the regular 30 μg adult dose in adolescents.
Study assessed various booster regimens to evaluate their effectiveness.
Heterologous regimens may offer a more efficient approach for COVID-19 booster campaigns in adolescent populations.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Study found heterologous COVID-19 vaccination improves immune response in adolescents, suggesting its effectiveness in booster campaigns.

Abstract

All booster regimens evaluated elicited a robust immune response. 10 μg fractional adult BNT162b2 vaccine demonstrated similar immunogenicity compared with 30 μg BNT162b2 and superior immunogenicity compared with 10 μg paediatric BNT162b2 vaccine. Fractional doses of the adult BNT162b2 vaccine are an alternative to the paediatric formulation for booster campaigns in adolescents.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kelly et al. (2025) studied this question.

synapsesocial.com/papers/694028d52d562116f2900b55 https://doi.org/10.1016/j.jinf.2025.106663

View Full Paper

Ask AI

Bookmark

Share

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading